MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM

Keskin, Havva; ARIKAN, Şenay; USTA, Tuba; CARLIOĞLU, AyŞe; ÇADIRCI, Kenan; OĞUZ, İsra

MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM

Kenan ÇADIRCI, (Sağlık Bilimleri Üniversitesi, Erzurum Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Erzurum, Türkiye)

İsra OĞUZ, (Medeniyet Üniversitesi, Göztepe Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İstanbul, Türkiye)

Tuba USTA, (Medeniyet Üniversitesi, Göztepe Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İstanbul, Türkiye)

Ayşe CARLIOĞLU, (Sağlık Bilimleri Üniversitesi, Erzurum Bölge Eğitim ve Araştırma Hastanesi, Endokrinoloji Bölümü, Erzurum, Türkiye)

Havva KESKİN, (Medeniyet Üniversitesi, Göztepe Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İstanbul, Türkiye)

Şenay ARIKAN (Kırıkkale Üniversitesi, Tıp Fakültesi, Endokrinoloji Bölümü, Kırıkkale, Türkiye)

Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi

0 0

Yıl: 2019 Cilt: 52 Sayı: 2 Sayfa Aralığı: 128 - 132 Metin Dili: İngilizce İndeks Tarihi: 04-11-2020

MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM

Öz:

INTRODUCTION: Previous studies have shown that idiopathichypogonadotropic hypogonadism (IHH) patients with lowtestosterone levels lead to an impaired glucose metabolism and anincreased cardiovascular risk. Monocyte to high-density lipoproteincholesterol (HDL-C) ratio (MHR) also has been shown to be anindicator of inflammation and cardiovascular risk. The purpose ofthe present study is to investigate MHR in the male with IHH.MATERIAL AND METHODS: This study includes 31 men withIHH without previous treatment for the disease and 44 healthymen. The blood samples, anthropometric measures, and physicalexamination were undertaken by all the participants.RESULTS: Mean ages of the IHH patients and the healthy controlswere 22.5±7.2 years vs. 22.9±6.4 years. There was no statisticallysignificant difference between the patients and controls in termsof the mean HDL-C, mean monocyte count, and mean MHR.The MHR also was not correlated with the other hematologicalparameters, inflammatory parameters, and the total testosteronelevel.CONCLUSION: MHR has been shown to be an indicator ofcardiovascular risk in previous studies but we could not detect anincreased MHR value in patients with IHH in this study.

Anahtar Kelime:

ERKEK İDİOPATİK HİPOGONADOTROPİK HİPOGONADİZMLİ HASTALARDA MONOSİT/ HDL ORANI

Öz:

AMAÇ: Önceki çalışmalar, düşük testosteron düzeylerine sahip idiopatik hipogonadotropik hipogonadizm (İHH) hastalarında bozulmuş glukoz metabolizmasına ve artmış kardiyovasküler riske yatkınlık olduğunu göstermiştir. Monosit/yüksek yoğunluklu lipoprotein kolesterol (HDL-C) oranı (MHR) de inflamasyon ve kardiyovasküler risk göstergesi olarak gösterilmiştir. Bu çalışmanın amacı, İHH tanılı erkek hastalarda MHR'yi araştırmaktır. GEREÇ VE YÖNTEMLER: Bu çalışmaya daha önce tedavi almamış İHH tanısı olan 31 erkek hasta ve sağlıklı 44 erkek dahil edildi. Tüm katılımcıların kan örneklemesi, antropometrik ölçümleri ve fizik muayeneleri yapıldı. BULGULAR: İHH hastalarının yaş ortalaması 22,5±7,2 yıl ve sağlıklı kontrollerin yaş ortalaması ise 22,9±6,4 yıl idi. Hastalar ve kontroller arasında ortalama HDL-kolesterol, ortalama monosit sayısı ve ortalama MHR açısından istatistiksel olarak anlamlı bir fark yoktu. MHR ayrıca diğer hematolojik parametreler, enflamatuar parametreler ve toplam testosteron seviyesi ile korele değildi. SONUÇLAR: Önceki çalışmalarda MHR'nin kardiyovasküler riskin bir göstergesi olduğu gösterilmiştir, ancak bu çalışmada İHH hastalarında artmış bir MHR değeri tespit edemedik.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1.)Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics (Sao Paulo). 2013;68 Suppl 1:81-8.
2.)Tang RY, Chen R, Ma M, Lin SQ, Zhang YW, Wang YP. Clinical characteristics of 138 Chinese female patients with idiopathic hypogonadotropic hypogonadism. Endocr Connect. 2017 Nov;6(8):800-10. doi: 10.1530/EC-17-0251. Epub 2017 Oct 10.
3.)Özbey İ. Treatment of hypogonadotropic hypogonadism. Turkiye Klinikleri J Urology-Special Topics. 2017;10(1):19-27
4.)Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2006 Jan;91(1):345-7. Epub 2005 Nov 1. doi:10.1210/jc.2005-1097
5.)Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res.2007 May; 39(5), 366–71. doi: 10.1055/s-2007-976543
6.)Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10. doi:10.1161/01. CIR.0000/29535.04194.38
7.)World Health Organization. Cardiovascular Disease (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovasculardiseases-%28cvds%29 accessed date: 01.04.2019
8.)Doğan BA, Karakılıç E, Tuna MM, Arduç A, Berker D, Güler S. Effect of androgen replacement therapy on atherosclerotic risk markers in youngto-middle-aged men with idiopathic hypogonadotropic hypogonadism. Clin Endocrinol (Oxf) 2015;82:422–8. doi:10.1111/cen.12617
9.)Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010 Nov;73(5):602-12. doi: 10.1111/j.1365-2265.2010.03845.x.
10.)Parihar A, Eubank TD, Doseff AI. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death.J Innate Immun. 2010;2(3):204-15. doi: 10.1159/000296507. Epub 2010 Mar 16.
11.) Kratofil RM, Kubes P, Deniset JF. Monocyte conversion during inflammation and injury. Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):35-42. doi: 10.1161/ATVBAHA.116.308198. Epub 2016 Oct 20.
12.)Leentjens J, Bekkering S, Joosten LAB, Netea MG, Burgner DP, Riksen NP. Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis. Circ Res. 2018 Mar 2;122(5):664-9. doi: 10.1161 / CIRCRESAHA. 117.312465. Epub 2018 Jan 24
13.)Akboga MK, Balci KG, Maden O, et al. Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark. Med.2016; 10(4), 375–83. doi: 10.2217/bmm-2015-0050
14.)Kosmas CE, Martinez I, Sourlas A, et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018 Mar 28;7:212525. doi: 10.7573/dic.212525. eCollection 2018.
15.)Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001 Oct;15(12):2073-84. doi: 10.1096/ fj.01-0273rev
16.)Korkmaz A, Demir M, Unal S, et al. Monocyte-to-high density lipoprotein ratio (MHR) can predict the significance of angiographically intermediate coronary lesions. Int J Cardiovasc Acad. 2017;3(1-2):16-20. doi: 10.1016/j.ijcac.2017.05.008
17.)Yilmaz M, Kayancicek H. A new inflammatory marker: elevated monocyte to HDL cholesterol ratio associated with smoking. J Clin Med. 2018; 7(4), 76. doi: 10.3390/jcm7040076
18.)Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014 Aug;46(8):1619-25. doi: 10.1007/s11255-014-0730-1. Epub 2014 May 23.
19.)Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. . PLoS One. 2013 Apr 18;8(4):e61466. doi: 10.1371/journal. pone.0061466. Print 2013
20.)Bianchi VE. The Anti-inflammatory effects of testosterone. J Endocr Soc. 2019 Jan 1; 3(1): 91–107. doi: 10.1210/js.2018-00186
21.)Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011 Jul;34(7):1669-75. doi: 10.2337/dc10-2339.
22.)Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology. 2004, 25(1), 4–7. doi:10.1016/j.it.2003.10.013
23.)Chen JW, Li C, Liu ZH, et al. The role of monocyte to high – density lipoprotein cholesterol ratio in prediction of carotid intima-media thickness in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2019 Apr 4;10:191. doi: 10.3389/fendo.2019.00191. eCollection 2019.
24.)You S, Zhong C, Zheng D,et al. Monocyte to HDL cholesterol ratio is associated with discharge and 3-month outcome in patients with acute intracerebral hemorrhage. J Neurol Sci. 2017 Jan 15;372:157-161. doi: 10.1016/j.jns.2016.11.022. Epub 2016 Nov 12.

APA	ÇADIRCI K, OĞUZ İ, USTA T, CARLIOĞLU A, Keskin H, ARIKAN Ş (2019). MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. , 128 - 132.
Chicago	ÇADIRCI Kenan,OĞUZ İsra,USTA Tuba,CARLIOĞLU AyŞe,Keskin Havva,ARIKAN Şenay MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. (2019): 128 - 132.
MLA	ÇADIRCI Kenan,OĞUZ İsra,USTA Tuba,CARLIOĞLU AyŞe,Keskin Havva,ARIKAN Şenay MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. , 2019, ss.128 - 132.
AMA	ÇADIRCI K,OĞUZ İ,USTA T,CARLIOĞLU A,Keskin H,ARIKAN Ş MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. . 2019; 128 - 132.
Vancouver	ÇADIRCI K,OĞUZ İ,USTA T,CARLIOĞLU A,Keskin H,ARIKAN Ş MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. . 2019; 128 - 132.
IEEE	ÇADIRCI K,OĞUZ İ,USTA T,CARLIOĞLU A,Keskin H,ARIKAN Ş "MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM." , ss.128 - 132, 2019.
ISNAD	ÇADIRCI, Kenan vd. "MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM". (2019), 128-132.

APA	ÇADIRCI K, OĞUZ İ, USTA T, CARLIOĞLU A, Keskin H, ARIKAN Ş (2019). MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, 52(2), 128 - 132.
Chicago	ÇADIRCI Kenan,OĞUZ İsra,USTA Tuba,CARLIOĞLU AyŞe,Keskin Havva,ARIKAN Şenay MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi 52, no.2 (2019): 128 - 132.
MLA	ÇADIRCI Kenan,OĞUZ İsra,USTA Tuba,CARLIOĞLU AyŞe,Keskin Havva,ARIKAN Şenay MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.52, no.2, 2019, ss.128 - 132.
AMA	ÇADIRCI K,OĞUZ İ,USTA T,CARLIOĞLU A,Keskin H,ARIKAN Ş MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2019; 52(2): 128 - 132.
Vancouver	ÇADIRCI K,OĞUZ İ,USTA T,CARLIOĞLU A,Keskin H,ARIKAN Ş MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2019; 52(2): 128 - 132.
IEEE	ÇADIRCI K,OĞUZ İ,USTA T,CARLIOĞLU A,Keskin H,ARIKAN Ş "MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM." Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, 52, ss.128 - 132, 2019.
ISNAD	ÇADIRCI, Kenan vd. "MONOCYTE TO HDL-CHOLESTEROL RATIO IN MALE WITH HYPOGONADOTROPIC HYPOGONADISM". Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi 52/2 (2019), 128-132.